| LHX |
Report |
2Q26 adjusted diluted EPS |
BEAT |
pred ~$2.85 vs. cons $2.80 |
MEDIUM |
| LHX |
Report |
2Q26 revenue |
BEAT |
pred ~$5.92B vs. cons $5.81B |
MEDIUM |
| LHX |
Report |
2Q26 free cash flow |
BEAT |
pred ~$0.62B vs. cons $0.56B |
LOW |
| LHX |
Guide |
FY26 revenue guidance |
BETTER |
guide ~$23.5B vs. cons $23.34B (FY2026) |
MEDIUM |
| LHX |
Guide |
FY26 adjusted EPS guidance |
BETTER |
guide ~$11.60 vs. cons $11.54 (FY2026) |
MEDIUM |
| LHX |
Guide |
FY26 free-cash-flow guidance |
LOWER |
guide ~$3.00B vs. cons $3.02B (FY2026) |
MEDIUM |
| LHX |
Guide |
FY26 segment operating-margin guidance |
UNCHANGED |
guide ~16.0% vs. cons 16.0% (FY2026) |
HIGH |
| LHX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.2% |
— |
MEDIUM |
| LHX |
Return |
5-day cumulative residual |
+4.5% (FOLLOW-THROUGH) |
A ~$0.05 EPS beat and ~$0.11B revenue beat, paired with a ~$0.16B revenue-guide increase versus consensus, supports positive FY26 and FY27 estimate revisions; retained ~$3.00B FCF guidance limits the upside but does not create an out-period earnings hole. |
MEDIUM |